Patents Examined by Daniel R Carcanague
  • Inhibitors of Rho associated coiled-coil containing protein kinase
    Patent number: 11479533
    Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: October 25, 2022
    Assignee: Kadmon Corporation, LLC
    Inventors: Eduardas Skucas, Kevin G. Liu, Ji-In Kim, Masha V. Poyurovsky, Rigen Mo, Jingya Zhang
  • Macrocyclic chlorine substituted indole derivatives
    Patent number: 11478451
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: October 25, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Rauh, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Katrin Nowak-Reppel, Chris Lemke, Michael H. Serrano-Wu, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven J. Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren, Rebecca Ann Harvey, Daniel Payne, Thomas Pesnot, Craig Wilson
  • S1P3 antagonists
    Patent number: 11472772
    Abstract: The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: October 18, 2022
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Chiara Caramelli, Cesare Federico, Emanuele Gabellieri, Matteo Magnani, Iolanda Micco, Georg C. Terstappen
  • Compound, ink, resist composition for color filter, sheet for heat-sensitive transfer recording, and toner
    Patent number: 11472962
    Abstract: An object of the present invention is to provide a compound exhibiting a cyan color having properties such as high chroma, high light fastness, and high solubility. The compound is represented by the following General Formula (1). In Formula (1), R1 and R2 each independently represent a linear, branched, or cyclic alkyl group having 6 or more and 12 or fewer carbon atoms, R3 represents a 4-alkylphenyl group, a 4-halogenated phenyl group, or a 3-alkoxyphenyl group, R4 represents a linear, branched, or cyclic alkyl group having 1 or more and 8 or fewer carbon atoms, and R5 represents a linear, branched, or cyclic alkyl group having 1 or more and 8 or fewer carbon atoms or a benzyl group.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: October 18, 2022
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Taichi Shintou, Koromo Shirota, Ai Hayakawa, Tsuyoshi Santo
  • Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
    Patent number: 11466003
    Abstract: Provided are a nitrogenous heterocyclic aromatic compound, a preparation method therefor, a pharmaceutical composition thereof, and an application thereof. The nitrogenous heterocyclic aromatic compound can be used for treating and/or preventing various diseases mediated by ALK5.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: October 11, 2022
    Assignee: SHANGHAI YINGLI PHARMACEUTICAL CO., LTD
    Inventors: Zusheng Xu, Yangtong Lou, Li Chen
  • Substituted propanamides as inhibitors of nucleases
    Patent number: 11453663
    Abstract: Compounds represented by the structural formula (1) where R1, R2, R3, R4, R5, R6 are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: September 27, 2022
    Assignee: MASARYKOVA UNIVERZITA
    Inventors: Kamil Paruch, Benoit Carbain, Stepan Havel, Vit Vsiansky, Fedor Nikulenkov, Lumir Krejci
  • Substituted eneoxindoles and uses thereof
    Patent number: 11453681
    Abstract: The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: September 27, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Kristyna M. Elbel, Rao V. Kalla, Samuel E. Metobo, Scott A. Mitchell, Thao D. Perry, Scott P. Simonovich, Christopher A. Ziebenhaus
  • Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof
    Patent number: 11447469
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: September 20, 2022
    Assignees: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
  • Macrocyclic chlorine substituted indole derivatives
    Patent number: 11447504
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: September 20, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Rauh, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Katrin Nowak-Reppel, Jérémie Xavier Mortier, Patrick R. McCarren, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven J. Ferrara, Laura Furst, Guo Wei, Rebecca Ann Harvey, Daniel Payne, Thomas Pesnot, Craig Wilson
  • Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis
    Patent number: 11447482
    Abstract: Novel substituted imidazopyridine and oxazolopyridine compounds that are useful as inhibitors of HIF-2? and inducers of ferroptosis through perturbations in iron metabolism, synthetic methods for making said compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions to treat disorders associated with dysfunction of HIF-2? or iron metabolism.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 20, 2022
    Assignee: KUDA THERAPEUTICS, INC.
    Inventors: Xiaohui Liu, Mei Yee Koh
  • Aromatic heterocyclic substituted olefin compound, preparation method for same, pharmaceutical composition of same, and applications thereof
    Patent number: 11447490
    Abstract: Provided in the present application are an aromatic heterocyclic substituted olefin compound, a preparation method for same, a pharmaceutical composition of same, and applications thereof. The aromatic heterocyclic substituted olefin compound of the present invention is a novel ALK5 inhibitor and is for use in treating and/or preventing various ALK5-mediated diseases.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: September 20, 2022
    Assignee: SHANGHAI YINGLI PHARMACEUTICAL CO., LTD
    Inventors: Zusheng Xu, Yangtong Lou, Li Chen, Kun Zeng, Qingrui Sun, Xiaoli Lei
  • Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients
    Patent number: 11439632
    Abstract: Disclosed herein are methods and compositions for administering immunotherapy to a subject in need thereof and for treating a subject in need thereof, where in the methods the subject is administered an effective amount of an inhibitor of nNOS for inducing an immunotherapeutic response in the subject and for treating the subject. The disclosed methods and composition may be utilized for treating a subject having a cell proliferative disease or disorder such as melanoma.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: September 13, 2022
    Assignees: Northwestern University, Chapman University
    Inventors: Richard B. Silverman, Sun Yang
  • Pyrimidine TBK/IKKe inhibitor compounds and uses thereof
    Patent number: 11440899
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: September 13, 2022
    Assignee: Merck Patent GmbH
    Inventors: Srinivasa R. Karra, Yufang Xiao, Brian Sherer, Eugene Checkler
  • p38? mitogen-activated protein kinase inhibitors
    Patent number: 11440918
    Abstract: Disclosed herein are p38? mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and therapeutic methods of using the p38? mitogen-activated protein kinase inhibitors.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: September 13, 2022
    Assignee: GEN1E LIFESCIENCES INC.
    Inventors: Adam Galan, Wendy Luo, Ritu Lal
  • Substituted macrocyclic indole derivatives
    Patent number: 11440923
    Abstract: The present invention relates to substituted macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: September 13, 2022
    Inventors: Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Rauh, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Mönning, Katrin Nowak-Reppel, Sven Wittrock, David McKinney, Michael H. Serrano-Wu, Chris Lemke, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven J. Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren, Rebecca Ann Harvey
  • Substituted dihydrobenzoxazinones, dihydroquinolones, and methods of their use and synthesis
    Patent number: 11440892
    Abstract: Disclosed are dihydrobenzoxazinone compounds, dihydroquinolone compounds, and methods of their synthesis. The disclosed compounds may be prepared by reacting a benzoxazinedione compound and a ketone compound in the presence of an N-heterocyclic carbine (NHC) catalyst to perform a NHC-catalyzed decarboxylative cycloaddition. The disclosed compounds may be utilized to treat diseases and disorders associated with the biological activity of dihydrobenzoxazinone compounds and dihydroquinolone compounds.
    Type: Grant
    Filed: July 3, 2020
    Date of Patent: September 13, 2022
    Assignee: Northwestern University
    Inventors: Karl A. Scheidt, Ansoo Lee
  • Compound, ink, resist composition for color filter, sheet for heat-sensitive transfer recording, and toner
    Patent number: 11434375
    Abstract: An object of the present invention is to provide a compound exhibiting a cyan color having properties such as high chroma, high light fastness, and high solubility. The compound is represented by the following General Formula (1). In Formula (1), R1 and R2 each independently represent a linear, branched, or cyclic alkyl group having 6 or more and 12 or fewer carbon atoms, R3 represents a 4-alkylphenyl group, a 4-halogenated phenyl group, or a 3-alkoxyphenyl group, R4 represents a linear, branched, or cyclic alkyl group having 1 or more and 8 or fewer carbon atoms, and R5 represents a linear, branched, or cyclic alkyl group having 1 or more and 8 or fewer carbon atoms or a benzyl group.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: September 6, 2022
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Taichi Shintou, Koromo Shirota, Ai Hayakawa, Tsuyoshi Santo
  • Pyrimidine derivatives for prevention and treatment of bacterial infections
    Patent number: 11434241
    Abstract: Pyrimidine derivatives of formula (I): optionally with a detectable isotope, pharmaceutical composition and method of preparation thereof. Pyrimidine derivatives for use in treatment or prevention of bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. Pyrimidine derivatives for use as radiotracer in diagnosing or prognosing bacterial infection in a host mammal.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: September 6, 2022
    Assignee: UNIVERSITÉ DE LIÈGE
    Inventors: Patrizio Lancellotti, Cécile Oury, Bernard Pirotte
  • Purification of cannabinoids from crude cannabis oil
    Patent number: 11434219
    Abstract: The present disclosure is generally directed to methods for purifying cannabinoids from Cannabis plants.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: September 6, 2022
    Assignee: TABA IP, LLC
    Inventors: Joshua Mayo, Aaron Rieder
  • Prolyl hydroxylase inhibitors and methods of use
    Patent number: 11426393
    Abstract: The present disclosure relates to HIF-1? prolyl hydroxylase inhibitors, compositions which comprise the HIF-1? prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: August 30, 2022
    Assignee: Akebia Therapeutics, Inc.
    Inventors: Richard Masaru Kawamoto, Shengde Wu, Artem G. Evdokimov, Kenneth D. Greis, Angelique Sun Boyer, Namal C. Warshakoon